Avalo Therapeutics (AVTX) financial statements
Avalo Therapeutics reported revenue of $59,000 in fiscal 2025, down 28.1% a year over 9 years.
Net income was -$78M and the operating margin -123601.7%, against -1394.6% in 2016.
The diluted share count rose 52% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Avalo Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $28M | $7M | $7M | $7M | $5M | $18M | $2M | $441,000 | $59,000 |
| Cost of revenue | $0 | $635,648 | $3M | -$566,523 | $300,000 | $1M | $3M | $1M | — | — |
| Gross profit | $1M | $27M | $4M | $7M | $6M | $4M | $15M | $640,000 | — | — |
| Research and development | $10M | $4M | $6M | $12M | $32M | $60M | $31M | $14M | $24M | $50M |
| Selling, general and admin | $7M | $9M | $11M | $12M | $20M | $27M | $21M | $10M | $17M | $23M |
| Operating income | -$16M | $14M | -$35M | -$16M | -$73M | -$82M | -$37M | -$27M | -$69M | -$73M |
| Pre-tax income | — | — | — | — | — | — | -$42M | -$32M | -$35M | -$78M |
| Income tax | $0 | $2M | -$49,466 | $280,316 | -$3M | -$196,000 | $28,000 | $14,000 | $114,000 | $165,000 |
| Net income | -$16M | $12M | -$40M | -$16M | -$64M | -$84M | -$42M | -$32M | -$35M | -$78M |
| EPS (diluted) | -$1.87 | $0.42 | -$1.20 | — | — | — | -$1,063.00 | -$113.58 | -$20.91 | -$5.84 |
| Diluted shares | 9M | 19M | 35M | — | — | — | 0M | 0M | 7M | 13M |
| Gross margin | 100.0% | 97.7% | 53.6% | 108.4% | 95.5% | 72.4% | 81.0% | 33.3% | — | — |
| Operating margin | -1394.6% | 49.9% | -503.4% | -239.1% | -1087.4% | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% |
| Net margin | -1428.6% | 42.7% | -569.9% | -238.1% | -947.9% | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
Balance sheet
Fiscal years, from Avalo Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $5M | $2M | $11M | $4M | $19M | $55M | $13M | $7M | $135M | $98M |
| Receivables | — | — | — | — | — | — | $0 | — | — | — |
| Inventory | $0 | $382,153 | $317,923 | $21,334 | $3,000 | $38,000 | $20,000 | $0 | — | — |
| Total current assets | $6M | $11M | $22M | $18M | $26M | $62M | $16M | $8M | $139M | $105M |
| Property, plant and equipment | $43,243 | $44,612 | $586,512 | $1M | — | — | — | — | — | — |
| Goodwill | $0 | $12M | $14M | $14M | $14M | $14M | $14M | $11M | $11M | $11M |
| Total assets | $6M | $43M | $70M | $36M | $44M | $80M | $33M | $21M | $151M | $116M |
| Total current liabilities | $4M | $11M | $26M | $12M | $15M | $20M | $22M | $5M | $7M | $13M |
| Long-term debt | $0 | $0 | $14M | — | — | — | — | — | — | — |
| Total liabilities | $6M | $15M | $49M | $15M | $19M | $57M | $44M | $14M | $18M | $33M |
| Shareholders' equity | $207,002 | $28M | $21M | $21M | $25M | $23M | -$11M | $7M | $133M | $83M |
| Net debt | -$3M | -$2M | $5M | -$4M | -$19M | -$55M | -$13M | -$7M | -$135M | -$16M |
Cash flow
Fiscal years, from Avalo Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15M | $13M | -$3M | -$19M | -$41M | -$71M | -$27M | -$31M | -$49M | -$51M |
| Capital spending | $34,883 | $23,325 | $564,415 | $262,013 | $63,000 | $113,000 | $95,000 | $158,000 | $0 | — |
| Free cash flow | -$15M | $13M | -$4M | -$19M | -$41M | -$71M | -$27M | -$31M | -$49M | — |
| Stock-based compensation | $2M | $1M | $2M | $3M | $7M | $8M | $8M | $3M | $6M | $14M |
| Net borrowing | -$3M | -$2M | $0 | -$256,140 | $0 | $0 | $0 | -$21M | $0 | — |
| Free cash flow margin | -1267.0% | 45.1% | -52.5% | -287.3% | -606.1% | -1315.4% | -148.7% | -1602.8% | -11123.8% | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AVTX.
Open AVTX in InvestinglyQuestions
What was Avalo Therapeutics's revenue in 2025?
$59,000 in fiscal 2025, from its 10-K filing.
From Avalo Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.